总生存期-话题@MedSci

#总生存期#

65篇内容 | 2826人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1515996, encodeId=baf6151599695, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期, objectType=article, longId=48929, objectId=a5c648929a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c648929a3, replyNumber=0, likeNumber=65, createdTime=2015-04-04, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c648929a3, moduleTitle=Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5c648929a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515995, encodeId=9167151599591, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）, objectType=article, longId=40872, objectId=1489408e2f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1489408e2f5, replyNumber=0, likeNumber=0, createdTime=2014-10-04, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1489408e2f5, moduleTitle=ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1489408e2f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515994, encodeId=9a441515994c0, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, objectType=article, longId=40815, objectId=525640815a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525640815a4, replyNumber=0, likeNumber=65, createdTime=2014-10-01, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525640815a4, moduleTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525640815a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515993, encodeId=a7961515993dc, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASCO 2014：ADT+多西他赛延长转移性前列腺癌总生存期（OS）, objectType=article, longId=35750, objectId=89fe35e50d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fe35e50d4, replyNumber=0, likeNumber=63, createdTime=2014-06-04, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fe35e50d4, moduleTitle=ASCO 2014：ADT+多西他赛延长转移性前列腺癌总生存期（OS）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fe35e50d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515992, encodeId=60fb151599226, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期, objectType=article, longId=33096, objectId=a01e33096d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a01e33096d2, replyNumber=0, likeNumber=58, createdTime=2014-04-11, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a01e33096d2, moduleTitle=安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a01e33096d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515991, encodeId=6688151599196, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=JCO：延迟强化治疗不能提高儿童ALL的预后和总生存期, objectType=article, longId=28880, objectId=2be628880db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2be628880db, replyNumber=0, likeNumber=0, createdTime=2014-01-05, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2be628880db, moduleTitle=JCO：延迟强化治疗不能提高儿童ALL的预后和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2be628880db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515990, encodeId=18fc1515990b9, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=礼来肺癌新药necitumumab III期试验改善总生存期, objectType=article, longId=23005, objectId=754e230053c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=754e230053c, replyNumber=0, likeNumber=69, createdTime=2013-08-17, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=754e230053c, moduleTitle=礼来肺癌新药necitumumab III期试验改善总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=754e230053c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515989, encodeId=c55015159897c, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=肺腺癌患者多西他赛联合ganetespib治疗可延长患者总生存期（GALAXY-1研究）, objectType=article, longId=21383, objectId=aad621383b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aad621383b3, replyNumber=0, likeNumber=74, createdTime=2013-07-15, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aad621383b3, moduleTitle=肺腺癌患者多西他赛联合ganetespib治疗可延长患者总生存期（GALAXY-1研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aad621383b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515988, encodeId=093e15159884f, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Cancer：ZD4054不延长特定前列腺癌患者的总生存期, objectType=article, longId=7933, objectId=20f5e933c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20f5e933c0, replyNumber=0, likeNumber=62, createdTime=2012-07-20, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20f5e933c0, moduleTitle=Cancer：ZD4054不延长特定前列腺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20f5e933c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515987, encodeId=065d151598e55, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=胃癌术后辅三联化疗药总生存期无获益, objectType=article, longId=7479, objectId=f5a7e4797c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5a7e4797c, replyNumber=0, likeNumber=65, createdTime=2012-06-30, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5a7e4797c, moduleTitle=胃癌术后辅三联化疗药总生存期无获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5a7e4797c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

总生存期

2020-05-29

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet Oncol：伏力诺他不能显著提高晚期恶性胸膜间皮瘤患者总生存期

2015-04-04

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ESMO 2014：帕妥珠单抗方案能显著提高转移性乳腺癌总生存期（CLEOPATRA研究）

2014-10-04

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

维汀联合希罗达显著延长HER2阴性乳腺癌总生存期

2014-10-01

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ASCO 2014：ADT+多西他赛延长转移性前列腺癌总生存期（OS）

2014-06-04

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期

2014-04-11

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

JCO：延迟强化治疗不能提高儿童ALL的预后和总生存期

2014-01-05

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

礼来肺癌新药necitumumab III期试验改善总生存期

2013-08-17

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

肺腺癌患者多西他赛联合ganetespib治疗可延长患者总生存期（GALAXY-1研究）

2013-07-15

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Cancer：ZD4054不延长特定前列腺癌患者的总生存期

2012-07-20

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

胃癌术后辅三联化疗药总生存期无获益

2012-06-30

科室
- - 订阅+
  - 更多科室
工具
服务